Wire · opportunities
FDA approves first drug shown to extend survival in infantile-onset Niemann-Pick disease type C
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 November 2026 · Fusion42 review
The FDA approved Lembaz (adrabetadex) as the first drug to extend survival in infantile-onset Niemann-Pick disease type C, reducing death risk by 55% in treated patients. The drug, given by spinal canal injection, carries a hearing loss warning and is expected to be commercially available in December.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 17 Nov 2026 and 18 Nov 2026.
◆ ◆ The Wire takeaway
You now have a clear market opening in rare genetic diseases after Lembaz sets a new survival benchmark for infantile Niemann-Pick type C. Prepare to engage specialists and advocacy groups as early commercial access will focus on this extremely rare patient group.
◆ Coverage
5 sources · first reported 17 Nov 2026 · latest 18 Nov 2026
◆ Related on Wire
◆ Topics